Narmada Movva, MD
Endocrinology, Diabetes & Metabolism · Attleboro, MANPI 1972930352
Payments from drug & device makers
Across 151 payments — averaging $20.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$444
- Abbott$346
- Tolmar, Inc.$334
- Lilly USA, LLC$291
- Antares Pharma, Inc.$273
- AstraZeneca$228
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,019100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 22 | $444 |
| Abbott | 18 | $346 |
| Tolmar, Inc. | 17 | $334 |
| Lilly USA, LLC | 15 | $291 |
| Antares Pharma, Inc. | 15 | $273 |
| AstraZeneca | 11 | $228 |
| Boehringer Ingelheim | 10 | $227 |
| Radius Health, Inc. | 7 | $141 |
| Sanofi | 6 | $114 |
| Amgen | 4 | $84 |
| Medtronic | 4 | $82 |
| Dexcom, Inc. | 4 | $74 |
| Cequr Corporation | 1 | $59 |
| Axsome Therapeutics, Inc. | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 3 | $51 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Acerus Pharmaceuticals Corporation | 2 | $30 |
| Mylan Specialty L.p. | 1 | $25 |
| Insulet Corporation | 1 | $24 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Alvogen Inc | 1 | $22 |
| Tandem Diabetes Care, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $17 |
| Verona Pharma, Inc. | 1 | $15 |
How this compares
$3,019 in reported general payments places this provider in the 65th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 517 | $652,207 |
| JardianceEmpagliflozin | 571 | $605,942 |
| TrulicityDulaglutide | 197 | $300,483 |
| MounjaroTirzepatide | 232 | $278,720 |
| Tresiba Flextouch U-200Insulin Degludec | 109 | $123,945 |
| Tresiba Flextouch U-100Insulin Degludec | 141 | $95,963 |
| TradjentaLinagliptin | 90 | $78,294 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 46 | $70,490 |
| FarxigaDapagliflozin Propanediol | 81 | $67,133 |
| TymlosAbaloparatide | 24 | $63,229 |
| Humalog Kwikpen U-100Insulin Lispro | 155 | $55,871 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 56 | $53,773 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 99 | $44,952 |
| JanuviaSitagliptin Phosphate | 36 | $42,417 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 225 | $38,765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $227 | $684,236661 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Levemir | $444 | $684,127579 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $291 | $589,018482 claims |
| AstraZenecaFarxiga | $228 | $67,13381 claims |
| Radius Health, Inc.Tymlos | $141 | $63,22924 claims |
| Alvogen IncTeriparatide | $22 | $22,14412 claims |
| AmgenProlia | $84 | $18,66211 claims |
| Antares Pharma, Inc.Xyosted | $273 | $10,10917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Attleboro
- David NathanBoston$9M
- Vanita ArodaBoston$4.2M
- George KingBoston$3.7M
- Karen MillerBoston$2.9M
- Steven GrinspoonBoston$2.7M
- Jason GagliaBoston$2.5M
- Tamer YacoubFall River$1.4M
- Elaine YuBoston$1.3M
- Osama HamdyBoston$1.1M
- Steven RussellBoston$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.